Diagnosing alveolar rhabdomyosarcoma: Morphology must be coupled with fusion confirmation

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2126-2128

  Wexler, Leonard H ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SURVIVAL; EDITORIAL; GENE EXPRESSION PROFILING; GENE FUSION; HISTOLOGY; HUMAN; MEDICAL LITERATURE; MORPHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RHABDOMYOSARCOMA; CHROMOSOME 8; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; EMBRYONAL RHABDOMYOSARCOMA; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; MORTALITY; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ONCOPROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 FOXO1A FUSION PROTEIN, HUMAN; PAX3 PROTEIN, HUMAN; PAX3-FOXO1A FUSION PROTEIN, HUMAN; PAX7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR PAX7;

CHROMOSOMES, HUMAN, PAIR 8; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; PREDICTIVE VALUE OF TESTS; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952311660     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.5339     Document Type: Editorial

References (27)

1. Riopelle JL, Thériault JP: A previously unrecognized type of soft tissue sarcoma: Alveolar rhabdomyosarcoma [French]. Annales d'anatomie pathologique 1:88-111, 1956
2. Enterline HT, Horn RC: Alveolar rhabdomyosarcoma: A distinctive tumor type. Am J Clin Pathol 24:356-366, 1958
3. Enzinger FM, Shiraki M: Alveolar rhabdomyosarcoma: An analysis of 110 cases. Cancer 24:18-31, 1969
4. Maurer HM, Beltangady M, Gehan EA, et al: The Intergroup Rhabdomyosarcoma Study-I: A final report. Cancer 61:209-220, 1988 (Pubitemid 18056471)
5. Maurer HM, Gehan EA, Beltangady M, et al: The Intergroup Rhabdomyosarcoma Study-II. Cancer 71:1904-1922, 1993
6. Heyn R, Beltangady M, Hays D, et al: Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study. J Clin Oncol 7:200-207, 1989 (Pubitemid 19048453)
7. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995
8. Crist WM, Anderson JR, Meza JL, et al: Intergroup Rhabdomyosarcoma Study-IV: Results for patients with non-metastatic disease. J Clin Oncol 12:3091-3102, 2001 (Pubitemid 32567502)
9. Neville HL, Andrassy RJ, Lobe TE, et al: Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: A preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Ped Surg 35:317-321, 2000
10. Raney RB, Meza J, Anderson JR, et al: Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group Protocols IRS-II through IRS-IV, 1978-1997. Med Pediatr Oncol 38:22-32, 2002
11. Meza JL, Anderson J, Pappo AS, et al: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group. J Clin Oncol 24:3844-3851, 2006 (Pubitemid 46630730)
12. Oberlin O, Rey A, Lyden E, et al: Prognostic factors in metastatic rhabdomyosarcomas: Results of pooled analysis from United States and European Cooperative Groups. J Clin Oncol 26:2384-2389, 2008
13. Arndt CAS, Stoner JA, Hawkins DS, et al: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 27:5182-5188, 2009
14. Galili N, Davis RJ, Fredericks WJ, et al: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhadomyosarcoma. Nature Genet 5:230-235, 1993 (Pubitemid 23330384)
15. David RJ, D'Cruz CM, Lovell MA, et al: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54:2869-2872, 1994 (Pubitemid 24187765)
16. Williamson D, Missiaglia E, de Reyniès A, et al: Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28:2151-2158, 2010
17. Davicioni E, Anderson MJ, Finckenstein FG, et al: Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am J Pathol 174:550-564, 2009
18. Wachtel M, Dettling M, Koscielniak E, et al: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64:5539-5545, 2004 (Pubitemid 39095545)
19. Davicioni E, Finckenstein FG, Shahbazian V, et al: Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66:6936-6946, 2006 (Pubitemid 44197668)
20. Laé M, Ahn EH, Mercado GE, et al: Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212:143-151, 2007 (Pubitemid 46852092)
21. Pandita A, Zielenska M, Thorner P, et al: Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia 1:262-275, 1999
22. Bridge JA, Liu J, Weibolt V, et al: Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: An Intergroup Rhabdomyosarcoma Study. Genes Chromosom Cancer 27:337-344, 2000 (Pubitemid 30127620)
23. Barr FG, Nauta LE, Davis RJ, et al: In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 5:15-21, 1996
24. Barr FG, Duan F, Smith LM, et al: Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosom Cancer 48:661-672, 2009
25. Kelly KM, Womer RB, Sorensen PHB, et al: Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15:1831-1836, 1997
26. Sorensen PH, Lynch JC, Qualman SJ, et al: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 20:2672-2679, 2002 (Pubitemid 34575640)
27. Barr FG, Qualman SJ, Macris MH, et al: Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62:4704-4710, 2002